Nanosonics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAN.AX research report →
Price Chart
About the company
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system, including all related supplies and accessories. Additionally, it dedicates resources to the exploration, development, and market launch of innovative infection control, decontamination products, and their associated technologies.
- CEO
- Michael C. Kavanagh
- IPO
- 2007
- Employees
- 470
- HQ
- Macquarie Park, NSW, AU
Get TickerSpark's AI analysis on NAN.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.09B
- P/E
- 53.62
- Fwd P/E
- 47.97
- PEG
- 2.13
- P/S
- 5.23
- P/B
- 5.02
- EV/EBITDA
- 32.17
- Div Yield
- 0.00%
- Gross Margin
- 77.17%
- Op Margin
- 8.95%
- Net Margin
- 9.91%
- ROE
- 9.57%
- ROIC
- 7.04%
Latest fiscal year · YoY change
- Revenue
- $198.93M+16.0%
- Gross Profit
- $155.66M+16.2%
- Op Income
- $8.93M
- Net Income
- $20.68M+59.4%
- EPS
- $0.07+62.4%
- OCF Growth
- +93.1%
- FCF Growth
- +74.0%
- 52W High
- $4.77
- 52W Low
- $2.94
- 50D MA
- $3.31
- 200D MA
- $3.61
- Beta
- 1.20
- RSI (14)
- 67
- Avg Volume
- 635.82K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nanosonics delivered a solid FY26 first half with 9% revenue growth, margin expansion despite tariff pressure, and reaffirmed full-year guidance while CORIS progressed toward commercialization.· February 23, 2026
- Revenue rose 9% to $102.2 million, with recurring revenue up 9% and capital revenue up 9%.
- Gross margin was 76.3%, down 2.2 points, mainly from U.S. tariffs, air freight, and product mix.
- Operating expenses increased just 4% to $69.5 million, helping operating margin expand 27% to $8.5 million.
- Installed base reached 38,080 devices, up 6%, and total installations rose 20% to 2,070 devices, including a record level of upgrades in North America.
- Management reaffirmed FY26 guidance: revenue growth of 8% to 12%, gross margin of 75% to 77%, and continued OpEx discipline.
- CORIS met key milestones, including regulatory registrations in Australia, Europe, and the U.K., with commercialization still expected to start in FY27.
For the half, revenue was $102.2 million, up 9% year over year, or 8% in constant currency. Gross profit margin was 76.3%, down 2.2 points year over year, and operating expenses rose 4% to $69.5 million. Operating profit was $8.5 million, EBIT was $8.4 million, down 3% reported but up 15% in constant currency, and profit before tax was $10.6 million, down 3% reported but up 13% in constant currency. Cash flow was a modest outflow of about $1.4 million, and the company ended with $159.8 million in cash and no debt. For FY26, management reaffirmed revenue growth guidance of 8% to 12% at constant currency, gross margin guidance of 75% to 77%, and said OpEx discipline would continue while investment in CORIS and other growth priorities remains in place. They also noted that if second-half revenue were recast at about $0.70/USD instead of the assumed $0.65, the revenue range would be approximately 3% lower.
Michael Kavanagh struck an upbeat but disciplined tone, saying the half was “really good and positive” financially and operationally. He emphasized the core trophon engine: installed-base growth, recurring revenue from consumables and service, and a record level of North American upgrades, while noting that trophon2 upgrades can still support future software-led value capture through trophon2 Plus. He also highlighted CORIS progress, including regulatory milestones and the start of Controlled Market Release in the U.K., while reiterating that commercialization is still expected in FY27.
Jason Burriss focused on operating leverage, margin discipline, and balance-sheet strength. He pointed to 38,080 devices in the global installed base, recurring revenue up 9%, total installations up 20% to 2,070 devices, capital revenue of $26.5 million, gross margin of 76.3%, and OpEx growth of just 4% to $69.5 million. He also explained the $0.7 million FX loss from revaluation of non-Australian dollar assets, said cash flow was an outflow of about $1.4 million due to CORIS inventory and buyback timing, and noted the company remains debt-free with $159.8 million in cash and about $4 million executed under the buyback.
Analysts focused on whether second-half growth can accelerate into the midpoint or top end of the 8% to 12% revenue guide, and management said that would depend on continued strong upgrade momentum and the usual second-half lift in service revenue. Questions also centered on the mix of upgrades between trophon2, trophon2 Plus, and trophon3, with management saying the current trophon2-heavy mix reflects budget timing, but the mix should move toward trophon3 over time and that there is no current friction around trophon3 pricing. On CORIS, management said OpEx should rise gradually rather than step sharply in FY27, because resource additions will be supplemental as commercialization ramps.
The bull case from this call is that Nanosonics continues to grow both its installed base and its recurring revenue streams while holding OpEx growth well below revenue growth. Management also sees a long runway from upgrades, with more than 25,000 trophon2 units in the market and a steady shift toward software-led value capture via trophon2 Plus and trophon3. CORIS adds a second growth avenue, with regulatory milestones already achieved and commercialization on track for FY27.
The main risks raised were tariff pressure, higher air freight, and mix effects that reduced gross margin to 76.3%. FX is also a headwind, with management saying a stronger Australian dollar could make the second-half revenue range about 3% lower and that unrealized FX losses could be larger than in H1. On CORIS, management is still early in commercialization, with broader rollout not expected until FY27 and OpEx likely to increase as the business adds resources to support it.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.3%
- Shares Outstanding
- 298.91M
- Float Shares
- 254.96M
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gofen & Glossberg LLC | 90.05K | 0 |
Held by 135 ETFs
Biggest fund positions in NAN.AX by dollar value.
Our NAN.AX coverage
Recent articles, reports, and earnings notes.
No research on NAN.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NAN.AX report →